ATLAS / Macro Radar / Reporting / ACRV

Acrivon Therapeutics, Inc. (ACRV) reporting calendar

Acrivon Therapeutics, Inc. files periodic reports with the SEC as ACRV on Nasdaq. Atlas tracks 15 filed reports for this issuer, each linked to its original EDGAR accession.

Next window
23 Jul 2026 – 3 Sep 2026
Latest report
10-Q
Period ended
31 Mar 2026
Filed
13 May 2026
Reports on record
15

How this window is derived. Derived from this issuer's own filing history: 9 periods at a median 91-day cadence, filed a median 44 days after period end. The SEC does not publish forward reporting dates and Atlas does not estimate one.

Open ACRV market profile Latest filing on SEC EDGAR ↗ Pharmaceutical Preparations reporting datesAll Nasdaq reporting dates

Filed periodic reports

FormPeriod endedFiledLagSEC accession
10-Q31 Mar 202613 May 202643 days0001193125-26-221634
10-K31 Dec 202519 Mar 202678 days0001193125-26-115123
10-Q30 Sep 202513 Nov 202544 days0001193125-25-280215
10-Q30 Jun 202513 Aug 202544 days0000950170-25-108054
10-Q31 Mar 202514 May 202544 days0000950170-25-071427
10-K31 Dec 202427 Mar 202586 days0000950170-25-046056
10-Q30 Sep 202413 Nov 202444 days0000950170-24-125929
10-Q30 Jun 202413 Aug 202444 days0000950170-24-095760
10-Q31 Mar 202414 May 202444 days0000950170-24-059084
10-K31 Dec 202328 Mar 202488 days0000950170-24-037618
10-Q30 Sep 20239 Nov 202340 days0000950170-23-061553
10-Q30 Jun 202311 Aug 202342 days0000950170-23-041593
10-Q31 Mar 20239 May 202339 days0000950170-23-019157
10-K31 Dec 202228 Mar 202387 days0000950170-23-010331
10-Q30 Sep 202215 Dec 202276 days0000950170-22-026622

Source: SEC EDGAR company submissions for CIK 0001781174. Atlas publishes filed facts only. The SEC does not publish forward reporting dates, so no announced future date is claimed here.